Recent Updates
Recently added Catalysts
IMVT Positive Sentiment Score: 75/100

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Tuesday, March 18, 2025 1 min read
Key Takeaway: Immunovant, Inc. will host an investor webcast on March 19 at 8:00 AM ET to discuss results from its Phase 3 study of batoclimab in myasthenia gravis and initial findings from its Phase 2b study in chronic inflammatory demyelinating polyneuropathy. The event will feature CEO Pete Salzmann and Roivant's CEO Matt Gline. A replay will be available after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is advancing its clinical programs for autoimmune diseases.
  • The upcoming webcast will provide insights into important study results.
  • Leadership from Immunovant and Roivant will present findings.

Full Press Release Details

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.

Webcast Details

The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19.Please clickhereto register for the event.The live webcast will also be available under theNews & Eventssection of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.

AboutImmunovant,Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visitimmunovant.com.

Contact:Renee Barnett, MBAChief Financial OfficerImmunovant, Inc.info@immunovant.com

Frequently Asked Questions

When is the Immunovant investor webcast scheduled?

The investor webcast is scheduled for March 19 at 8:00 AM ET.

What will be discussed during the webcast?

The webcast will review results from the Phase 3 study of batoclimab in myasthenia gravis and initial results from the Phase 2b study in CIDP.

Who will present at the webcast?

Pete Salzmann, CEO of Immunovant, and Matt Gline, CEO of Roivant, will present.

Will the webcast be available for replay?

Yes, a replay of the event and presentation will be available immediately after the webcast.

Tags: IMVT Viatris Investor Conferences Healthcare Immunovant batoclimab myasthenia gravis chronic inflammatory demyelinating polyneuropathy clinical-stage
Last updated: Mar 18, 2025